



Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.  
SUNOSI (Solriamfetol) Prior Authorization (PA)  
Pharmacy Benefits Prior Authorization Help Desk  
Length of Authorizations: Initial- 12 months; Continuation- 12 months

**Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage **SUNOSI (Solriamfetol)**. Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: [Pharmacy | Community Provider Portal | Kaiser Permanente](#)

**1 – Patient Information**

Patient Name: \_\_\_\_\_ Kaiser Medical ID#: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

**2 – Prescriber Information**

Is the prescriber a Pulmonologist (Sleep Specialist) or Neurologist?  No  Yes

If consulted with a specialist, specialist name and specialty: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_

Prescriber Address: \_\_\_\_\_

Prescriber Phone #: \_\_\_\_\_ Prescriber Fax #: \_\_\_\_\_

**3 – Pharmacy Information**

Pharmacy Name: \_\_\_\_\_ Pharmacy NPI: \_\_\_\_\_

Pharmacy Phone # \_\_\_\_\_ Pharmacy Fax #: \_\_\_\_\_

**4 – Drug Therapy Requested**

Drug 1: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

Drug 2: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

**5– Diagnosis/Clinical Criteria**

- 1. Is this request for initial or continuing therapy?  
 Initial therapy                       Continuing therapy, State date: \_\_\_\_\_
- 2. Indicate the Member’s diagnosis for the requested medication: \_\_\_\_\_

**Clinical Criteria:**

- 1. Member has a diagnosis of excessive daytime sleepiness in narcolepsy,  
 No  Yes
- 2. **AND** had adequate trial (≥2 months) of a preferred stimulant (methylphenidate, amphetamine salt combination, dextroamphetamine) **AND** modafinil/armodafinil, unless contraindicated,  
 No  Yes
- 3. **AND** member is 18-75 years of age  
 No  Yes

**- OR -**

- 4. Member has a diagnosis of hypersomnia associated with Obstructive Sleep Apnea,  
 No  Yes
- 5. **AND** had adequate trial (≥2 months) of modafinil/armodafinil, unless contraindicated  
 No  Yes

**For Continuation of Therapy, Please Respond to Additional Questions Below:**

- 1. Member continues to be under the care of a specialist,  
 No  Yes
- 2. **AND** the member has documentation of positive clinical response  
 No  Yes

**6 – Prescriber Sign-Off**

**Additional Information –**

- 1. **Please submit chart notes/medical records for the patient that are applicable to this request.**
- 2. **If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**I certify that the information provided is accurate. Supporting documentation is available for State audits.**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility